KCNK4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30332608	1.00	1/20
SCHEMBL27451203	0.77	1/20
SCHEMBL13973379	0.76	1/20
SCHEMBL21794942	0.68	1/20
SCHEMBL13740811	0.67	1/20
SCHEMBL10114367	0.66	1/20
SCHEMBL10114761	0.66	1/20
SCHEMBL10133403	0.66	1/20
SCHEMBL13204323	0.66	1/20
SCHEMBL3932997	0.65	1/20
SCHEMBL10599193	0.65	1/20
SCHEMBL16147668	0.63	1/20
SCHEMBL27451200	0.63	1/20
SCHEMBL1984153	0.62	1/20
SCHEMBL6722379	0.61	1/20
SCHEMBL2243918	0.61	1/20
SCHEMBL1071608	0.60	1/20
SCHEMBL1071610	0.60	1/20
SCHEMBL2252511	0.59	1/20
SCHEMBL27452500	0.59	1/20

Clinical trials — most relevant to KCNK4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Targeted Potassium Levels for Prevention of ICD Therapy	PHASE4	ACTIVE_NOT_RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Electrophysiological Effects of Potential QT Prolonging Drugs	PHASE1	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Peripheral KV7 Activation for Pain Relief	EARLY_PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
The Natural History of TRPV4 Neuropathy	nan	RECRUITING
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Headache Inducing Effect of NN414 in Migraine Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNK4 binder may also engage these)

Protein	Name	Similarity
G3V8V5	—	0.988	G3V8V5 →
O88454	—	0.984	O88454 →
Q6VV64	—	0.982	Q6VV64 →
Q6Q1P3	—	0.977	Q6Q1P3 →
KCNK18	Potassium channel subfamily K member 18	0.966	landscape →
Q9HB15	—	0.962	Q9HB15 →
A6QM06	—	0.962	A6QM06 →
A2RRU4	—	0.961	A2RRU4 →
Q6GQT6	—	0.961	Q6GQT6 →
Q12770	—	0.960	Q12770 →
P97260	—	0.959	P97260 →
KCNK17	Potassium channel subfamily K member 17	0.959	landscape →
Q5MNU5	—	0.959	Q5MNU5 →
KCNK13	Potassium channel subfamily K member 13	0.959	landscape →
Q9ERS1	—	0.958	Q9ERS1 →
Q0GA42	—	0.952	Q0GA42 →
SPPL2B	Signal peptide peptidase-like 2B	0.952	landscape →
Q9NRU3	—	0.952	Q9NRU3 →
Q7Z403	—	0.951	Q7Z403 →
Q96JH8	—	0.949	Q96JH8 →
Q8R1P5	—	0.949	Q8R1P5 →
Q9R283	—	0.947	Q9R283 →
P41155	—	0.947	P41155 →
Q8MIQ9	—	0.946	Q8MIQ9 →
Q0VF94	—	0.946	Q0VF94 →
Q04671	—	0.946	Q04671 →
Q69Z89	—	0.946	Q69Z89 →
MCOLN1	Mucolipin-1	0.945	landscape →
Q29RM4	—	0.945	Q29RM4 →
Q9UIX4	—	0.945	Q9UIX4 →